This review highlights the potential of pharmacogenetics and disease modifiers to develop personalized, more effective therapies for genetic ion channelopathies.
Authors
No takes yet. Share an insight, caveat, or question.
May inform personalized strategies in channelopathies; leaves open validation in prospective trials.
Imbrici et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: